Cardiff Oncology, Inc. CRDF
We take great care to ensure that the data presented and summarized in this overview for Cardiff Oncology, Inc. is accurate and up-to-date, based on a comprehensive analysis of 13F filing forms for institutional ownership and form 4 filings for insider transactions. Please note that this data may differ from other sources and should not be relied upon as the sole basis for investment decisions.
Top Institutions Holding CRDF
View all-
Vanguard Group Inc Valley Forge, PA1.92MShares$6.11 Million0.0% of portfolio
-
Laurion Capital Management LP New York, NY929KShares$2.95 Million0.04% of portfolio
-
Israel Englander Millennium Management LLC | New York, Ny683KShares$2.17 Million0.0% of portfolio
-
Black Rock Inc. New York, NY677KShares$2.15 Million0.0% of portfolio
-
Mai Capital Management551KShares$1.75 Million0.03% of portfolio
-
Geode Capital Management, LLC Boston, MA435KShares$1.38 Million0.0% of portfolio
-
Marshall Wace, LLP London, X0435KShares$1.38 Million0.0% of portfolio
-
Goldman Sachs Group Inc New York, NY286KShares$909,0790.0% of portfolio
-
Assenagon Asset Management S.A.253KShares$804,4820.0% of portfolio
-
Blair William & CO Chicago, IL172KShares$547,5320.0% of portfolio
Latest Institutional Activity in CRDF
Top Purchases
Top Sells
About CRDF
Cardiff Oncology, Inc., a clinical-stage oncology company, develops medicine treatment for cancer patients in California. Its lead drug candidate is onvansertib, an oral selective Polo-like Kinase 1 Inhibitor for anti-cancer therapeutics; CY140, an inhibitor of PLK1, PLK2, and PLK3 that is in phase 1/2 studies in solid tumors and leukemias; metastatic colorectal cancer that is in clinical trials; and TROV-054 is a Phase 1b/2 for FOLFIRI and bevacizumab. The company's TROV-053 is also in Phase II clinical trial in combination with Zytiga for metastatic castration-resistant prostate cancer. The company primarily serves pharmaceutical manufacturers. The company was formerly known as Trovagene, Inc. and changed its name to Cardiff Oncology, Inc. in May 2012. Cardiff Oncology, Inc. was incorporated in 1999 and is headquartered in San Diego, California.
Insider Transactions at CRDF
Insider Transaction List
View all| Date | Insider | Transaction | Ownership Type | Shares Traded | Value / Price |
|---|---|---|---|---|---|
|
Dec 19
2023
|
Gary W Pace Director |
BUY
Open market or private purchase
|
Direct |
30,000
+4.12%
|
$30,000
$1.37 P/Share
|
|
Nov 25
2022
|
Mark Erlander Chief Executive Officer |
BUY
Open market or private purchase
|
Direct |
10,000
+29.0%
|
$10,000
$1.43 P/Share
|
|
Sep 19
2022
|
Lale White Director |
BUY
Open market or private purchase
|
Indirect |
15,000
+11.65%
|
$15,000
$1.64 P/Share
|
|
Sep 16
2022
|
James O Armitage Director |
BUY
Open market or private purchase
|
Indirect |
13,000
+50.0%
|
$13,000
$1.56 P/Share
|
|
Sep 16
2022
|
James E. Levine Chief Financial Officer |
BUY
Open market or private purchase
|
Direct |
30,000
+33.33%
|
$30,000
$1.56 P/Share
|
|
Sep 15
2022
|
Renee P Tannenbaum Director |
BUY
Open market or private purchase
|
Direct |
10,000
+38.24%
|
$10,000
$1.72 P/Share
|
|
Sep 15
2022
|
Gary W Pace Director |
BUY
Open market or private purchase
|
Direct |
150,000
+18.87%
|
$150,000
$1.71 P/Share
|
|
Jul 05
2022
|
Lale White Director |
BUY
Exercise of conversion of derivative security
|
Indirect |
28,858
+22.61%
|
$57,716
$2.6 P/Share
|
|
Sep 21
2021
|
Gary W Pace Director |
BUY
Open market or private purchase
|
Direct |
30,000
+5.72%
|
$180,000
$6.75 P/Share
|
|
Sep 10
2021
|
James E. Levine Chief Financial Officer |
BUY
Open market or private purchase
|
Direct |
30,000
+29.52%
|
$180,000
$6.48 P/Share
|
|
Mar 26
2021
|
Rodney S Markin Director |
BUY
Open market or private purchase
|
Indirect |
2,900
+10.83%
|
$29,000
$10.32 P/Share
|
|
Mar 23
2021
|
Gary W Pace Director |
BUY
Open market or private purchase
|
Direct |
10,000
+0.72%
|
$100,000
$10.24 P/Share
|
|
Mar 23
2021
|
Mark Erlander Chief Executive Officer |
BUY
Open market or private purchase
|
Direct |
965
+6.25%
|
$9,650
$10.34 P/Share
|
|
Mar 23
2021
|
Vicki Kelemen Exec. VP and COO |
BUY
Open market or private purchase
|
Direct |
960
+13.69%
|
$9,600
$10.31 P/Share
|
|
Mar 23
2021
|
Gary S Jacob |
BUY
Open market or private purchase
|
Direct |
2,370
+5.12%
|
$23,700
$10.41 P/Share
|
|
Mar 22
2021
|
John P Brancaccio |
BUY
Open market or private purchase
|
Direct |
3,000
+19.66%
|
$30,000
$10.95 P/Share
|
|
Mar 19
2021
|
James O Armitage Director |
BUY
Open market or private purchase
|
Direct |
4,000
+21.63%
|
$40,000
$10.82 P/Share
|
|
Mar 18
2021
|
Gary W Pace Director |
BUY
Open market or private purchase
|
Direct |
3,000
+0.33%
|
$30,000
$10.56 P/Share
|
|
Mar 04
2021
|
Gary W Pace Director |
BUY
Open market or private purchase
|
Direct |
1,500
+0.33%
|
$13,500
$9.27 P/Share
|
|
Jan 02
2021
|
Mark Erlander Chief Executive Officer |
SELL
Payment of exercise price or tax liability
|
Direct |
113
-0.83%
|
-
|
Last 12 Months Summary
| Open market or private purchase | 30K shares |
|---|